Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement

Once-daily medications for the pharmacological management of ADHD in adults

Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment option for ADHD across all age groups. The current review's goals are (a) to critically examine the current state of knowledge regarding once-daily formulations of pharmacotherapies for treatment of adults with ADHD and (b) to provide clinicians with evidence-based information regarding the safety, efficacy and tolerability of once-daily medications for adult ADHD. The reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line therapeutic option for the treatment of adults with ADHD. The once-daily pharmacological agents are effective therapeutic options for the treatment of adults with ADHD. In the US, based on the available evidence, once-daily medications are currently underutilized in adults with ADHD compared to pediatric population.

Is quetiapine a drug of abuse? Reexamining the issue of addiction

BACKGROUND

The abuse and diversion of pharmacological agents with CNS mechanisms of action is an important concern from governmental, regulatory, public health and safety perspectives. In recent years, there have been an increased number of reports concerning the abuse and diversion of quetiapine in forensic population and in individuals with histories of substance abuse.

OBJECTIVE

To better understand this surging pattern the available body of evidence was critically examined.

METHODS

A literature search from January 1991 to July 2008 restricting papers to English and using PUBMED and PsychInfo was performed.

RESULTS

Nine papers were identified. The content of these papers is discussed in light of recent research on drug abuse.